Advertisement
Screener

Corbus Pharmaceuticals Holdings, Inc. (CRBP) Marketable Securities, Unrealized Gain (Loss)

1.9 / 5 stars · 29/75 Roast Me

Corbus Pharmaceuticals Holdings, Inc. Marketable Securities, Unrealized Gain (Loss)

Corbus Pharmaceuticals Holdings, Inc. (CRBP) reported Marketable Securities, Unrealized Gain (Loss) of $54.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.

Financial Statements › Income Statement › Other Income

us-gaap:MarketableSecuritiesUnrealizedGainLoss · last filed 2026-08-06

  • Corbus Pharmaceuticals Holdings, Inc. marketable securities, unrealized gain (loss) for the quarter ending 2026-06-30 was $54.00K.
  • Corbus Pharmaceuticals Holdings, Inc. marketable securities, unrealized gain (loss) for the quarter ending 2026-03-31 was -$108.00K.
  • Corbus Pharmaceuticals Holdings, Inc. marketable securities, unrealized gain (loss) for the quarter ending 2025-12-31 was -$50.00K.
  • Corbus Pharmaceuticals Holdings, Inc. marketable securities, unrealized gain (loss) for the quarter ending 2025-09-30 was $36.00K, a 93.95% decline year-over-year.
  • Corbus Pharmaceuticals Holdings, Inc. marketable securities, unrealized gain (loss) for fiscal 2025 was -$88.00K, a 344.44% decline from fiscal 2024.
  • Corbus Pharmaceuticals Holdings, Inc. marketable securities, unrealized gain (loss) for fiscal 2024 was $36.00K, a 71.20% decline from fiscal 2023.
  • Corbus Pharmaceuticals Holdings, Inc. marketable securities, unrealized gain (loss) for fiscal 2023 was $125.00K.
  • Corbus Pharmaceuticals Holdings, Inc. marketable securities, unrealized gain (loss) for fiscal 2022 was -$63.65K.
Period endMarketable Securities, Unrealized Gain (Loss) 3 monthMarketable Securities, Unrealized Gain (Loss) 3 month as first filedMarketable Securities, Unrealized Gain (Loss) 6 monthMarketable Securities, Unrealized Gain (Loss) 6 month as first filedMarketable Securities, Unrealized Gain (Loss) 9 monthMarketable Securities, Unrealized Gain (Loss) 9 month as first filedMarketable Securities, Unrealized Gain (Loss) 12 monthMarketable Securities, Unrealized Gain (Loss) 12 month as first filed
2026-06-30$54.00K
10-Q · filed 2026-08-06
-$54.00K
10-Q · filed 2026-08-06
-$104.00K
derived: sum of 3 quarters · filed 2026-08-06
-$68.00K
derived: sum of 4 quarters · filed 2026-08-06
2026-03-31-$108.00K
10-Q · filed 2026-05-12
-$158.00K
derived: sum of 2 quarters · filed 2026-05-12
-$122.00K
derived: sum of 3 quarters · filed 2026-05-12
-$138.00K
derived: sum of 4 quarters · filed 2026-08-06
2025-12-31-$50.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09
-$14.00K
derived: sum of 2 quarters · filed 2026-03-09
-$30.00K
derived: sum of 3 quarters · filed 2026-08-06
-$88.00K
10-K · filed 2026-03-09
2025-09-30$36.00K
10-Q · filed 2025-11-12
$20.00K
derived: sum of 2 quarters · filed 2026-08-06
-$38.00K
10-Q · filed 2025-11-12
-$210.00K
derived: sum of 4 quarters · filed 2026-08-06
2025-06-30-$16.00K
10-Q · filed 2026-08-06
-$74.00K
10-Q · filed 2026-08-06
-$246.00K
derived: sum of 3 quarters · filed 2026-08-06
$349.00K
derived: sum of 4 quarters · filed 2026-08-06
2025-03-31-$58.00K
10-Q · filed 2026-05-12
-$230.00K
derived: sum of 2 quarters · filed 2026-05-12
$365.00K
derived: sum of 3 quarters · filed 2026-05-12
$306.00K
derived: sum of 4 quarters · filed 2026-05-12
2024-12-31-$172.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09
$423.00K
derived: sum of 2 quarters · filed 2026-03-09
$364.00K
derived: sum of 3 quarters · filed 2026-03-09
$36.00K
10-K · filed 2026-03-09
2024-09-30$595.00K
10-Q · filed 2025-11-12
$536.00K
derived: sum of 2 quarters · filed 2025-11-12
$208.00K
10-Q · filed 2025-11-12
$214.00K
derived: sum of 4 quarters · filed 2025-11-12
2024-06-30-$59.00K
10-Q · filed 2025-08-05
-$387.00K
10-Q · filed 2025-08-05
-$381.00K
derived: sum of 3 quarters · filed 2025-08-05
-$365.00K
derived: sum of 4 quarters · filed 2025-08-05
2024-03-31-$328.00K
10-Q · filed 2025-05-06
-$326.95K
10-Q · filed 2024-05-07
-$322.00K
derived: sum of 2 quarters · filed 2025-05-06
-$306.00K
derived: sum of 3 quarters · filed 2025-05-06
-$261.00K
derived: sum of 4 quarters · filed 2025-05-06
2023-12-31$6.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-11
$22.00K
derived: sum of 2 quarters · filed 2025-03-11
$67.00K
derived: sum of 3 quarters · filed 2025-03-11
$125.00K
10-K · filed 2025-03-11
$124.54K
10-K · filed 2024-03-12
2023-09-30$16.00K
10-Q · filed 2024-11-07
$15.75K
10-Q · filed 2023-11-07
$61.00K
derived: sum of 2 quarters · filed 2024-11-07
$119.00K
10-Q · filed 2024-11-07
$118.06K
10-Q · filed 2023-11-07
$199.41K
derived: sum of 4 quarters · filed 2024-11-07
2023-06-30$45.00K
10-Q · filed 2024-08-06
$44.68K
10-Q · filed 2023-08-08
$103.00K
10-Q · filed 2024-08-06
$102.30K
10-Q · filed 2023-08-08
$183.41K
derived: sum of 3 quarters · filed 2024-08-06
$95.85K
derived: sum of 4 quarters · filed 2024-08-06
2023-03-31$57.62K
10-Q · filed 2024-05-07
$138.41K
derived: sum of 2 quarters · filed 2024-05-07
$50.85K
derived: sum of 3 quarters · filed 2024-05-07
$101.22K
derived: sum of 4 quarters · filed 2024-05-07
2022-12-31$80.78K
derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-12
-$6.77K
derived: sum of 2 quarters · filed 2024-03-12
$43.60K
derived: sum of 3 quarters · filed 2024-03-12
-$63.65K
10-K · filed 2024-03-12
2022-09-30-$87.55K
10-Q · filed 2023-11-07
-$37.18K
derived: sum of 2 quarters · filed 2023-11-07
-$144.43K
10-Q · filed 2023-11-07
-$197.91K
derived: sum of 4 quarters · filed 2023-11-07
2022-06-30$50.37K
10-Q · filed 2023-08-08
-$56.88K
10-Q · filed 2023-08-08
-$110.35K
derived: sum of 3 quarters · filed 2023-08-08
-$113.87K
derived: sum of 4 quarters · filed 2023-08-08
2022-03-31-$107.25K
10-Q · filed 2023-05-09
-$160.73K
derived: sum of 2 quarters · filed 2023-05-09
-$164.24K
derived: sum of 3 quarters · filed 2023-05-09
-$140.93K
derived: sum of 4 quarters · filed 2023-05-09
2021-12-31-$53.48K
derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-07
-$56.99K
derived: sum of 2 quarters · filed 2023-03-07
-$33.68K
derived: sum of 3 quarters · filed 2023-03-07
-$62.45K
10-K · filed 2023-03-07
2021-09-30-$3.51K
10-Q · filed 2022-11-08
$19.80K
derived: sum of 2 quarters · filed 2022-11-08
-$8.97K
10-Q · filed 2022-11-08
2021-06-30$23.31K
10-Q · filed 2022-08-09
-$5.45K
10-Q · filed 2022-08-09
2021-03-31-$28.77K
10-Q · filed 2022-05-10

Similar stocks

Stock NameCountryMarket CapPE Ratio
Annexon, Inc. (ANNX)United States$0.147B-4.22
SPRUCE BIOSCIENCES, INC. (SPRB)United States$0.142B-2.89
Korro Bio, Inc. (KRRO)United States$0.141B-1.81
Atrium Therapeutics, Inc. (RNA)United States$0.140B
Curanex Pharmaceuticals Inc (CURX)United States$0.138B
TuHURA Biosciences, Inc./NV (HURA)United States$0.134B-4.88
Unicycive Therapeutics, Inc. (UNCY)United States$0.134B-3.70
NRX Pharmaceuticals, Inc. (NRXP)United States$0.131B-6.31
MEDICINOVA INC (MNOV)United States$0.130B-6.04
IMMUNIC, INC. (IMUX)United States$0.127B-1.88